Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Janssen Pharmaceutica NV, Beerse, Belgium.
Lara J
LJ
Wolfson
University of Cologne, Cologne, Germany.
Judith
J
Gibbert
Janssen-Cilag, Neuss, Germany dwirth2@its.jnj.com.
Daniel
D
Wirth
University of Kiel, Kiel, Germany.
Roland
R
Diel
D000995:Antitubercular Agents / Q000191:economics / Q000627:therapeutic use*; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D064687:Diarylquinolines / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000191:economics; D024841:Fluoroquinolones / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009593:Nitroimidazoles / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000191:economics
D000995:Antitubercular Agents; D064687:Diarylquinolines; D024841:Fluoroquinolones; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; D011718:Pyrazinamide; C493870:bedaquiline